U.S. Food Stock News

Why Hologic (HOLX) is on investors’ radar today Hologic (HOLX) has drawn investor interest recently as its share price, which last closed at US$75.65, reflects mixed short term performance and a moderate gain over the past 3 months. Over the past month, Hologic’s return was roughly flat, while the past 3 months show a gain of about 1%. Over the past year, the stock’s total return of about 24% contrasts with a slight negative total return over 3 years and a modest gain over 5 years. These...

Recently, activist investor Land & Buildings raised its stake in Centerspace REIT to 9.19%, coinciding with Board Member Emily Nagle Green’s retirement and the declaration of a quarterly dividend. Taken together, the larger activist presence and board change may point to upcoming discussions around Centerspace’s capital allocation and portfolio direction. With Land & Buildings now owning over 9% of Centerspace, we’ll examine how this increased activist involvement could reshape its...

FuboTV (NYSE:FUBO) approved a reverse stock split and amended its bylaws to reflect the change. The reverse split has already been implemented, consolidating existing shares into a smaller number. These actions adjust the company’s share structure and may influence its exchange listing status and future financing options. FuboTV operates a live TV streaming platform focused on sports, news, and entertainment, positioning itself as an alternative to traditional cable bundles. The reverse...

Why Sealed Air Is On Investors’ Radar Sealed Air (SEE) has been drawing attention after recent share price moves, prompting investors to take a fresh look at its packaging business, current valuation signals, and how its returns have varied across different time frames. See our latest analysis for Sealed Air. The share price at US$42.08 has been relatively steady in the short term, while the 1 year total shareholder return of 76.16% contrasts with flat to slightly negative total shareholder...

Despite the fact that Pulmonx Corporation (NASDAQ:LUNG) stock rose 14% last week, insiders who sold US$371k worth of...

In March 2026, Worthington Enterprises, Inc. reported higher year-over-year third-quarter and nine-month sales and net income, continued its share repurchases, and its Board declared a US$0.19 per-share quarterly dividend payable on June 29, 2026. Together, the earnings growth, ongoing buybacks that have retired more than two-fifths of shares since 2014, and the uninterrupted dividend record since 1968 highlight the company’s long-running focus on returning cash to shareholders. Next, we’ll...

RCM Technologies (RCMT) has wrapped up FY 2025 with fourth quarter revenue of US$86.5 million, basic EPS of US$0.80 and net income of US$6.1 million. The trailing twelve months show revenue of US$319.4 million, EPS of US$2.19 and net income of US$16.3 million, with earnings growth of 22.4% over the past year. Over recent periods the company has seen revenue move from US$278.4 million to US$319.4 million on a trailing basis, alongside EPS shifting from US$1.72 to US$2.19. This ties into a net...

In recent months, Soleno Therapeutics has faced multiple securities class action lawsuits alleging that the company and certain executives failed to disclose material safety concerns and data integrity issues tied to the Phase 3 program for its Prader‑Willi syndrome drug DCCR, marketed as VYKAT XR. These legal challenges, centered on claims of undisclosed risks such as fluid retention, diabetes‑related markers, and high discontinuation rates, have intensified scrutiny of VYKAT XR’s clinical...

In recent days, Assured Guaranty director Francisco Borges sold 123,750 shares of the company, a transaction worth nearly US$9.93 million, marking a large reduction in his personal stake. This insider sale comes as Assured Guaranty balances strong profitability and a solid balance sheet with pressures from lower-yield AA business and its Assured Life Re annuity reinsurance expansion. We’ll now examine how Borges’ sizable insider sale could influence Assured Guaranty’s investment narrative,...

AI data centers, stubborn energy costs, and heightened geopolitical risk are all pushing reliable, carbon free power to the forefront of investment thinking. Nuclear sits at the center of that discussion, with governments, utilities, and large corporates all searching for 24/7 electricity that does not depend on weather or imported fossil fuels. Our Nuclear Renaissance screener is built to help you focus on listed companies most closely aligned with this long term trend. In this article, you...

For investors wondering if Turning Point Brands at around US$72.16 is still offering value or if the easy gains are behind it, this article focuses squarely on what the current price might be implying. The stock has pulled back sharply in the short term, with a 15.5% decline over the last 7 days and a 21.9% decline over the last 30 days, even though the 1 year return sits at 32.8% and the 3 year return is 254.2%. Recent market attention has centered on how this performance, including a year...

BlackSky Technology (NYSE:BKSY) received a sole source, multi year US$99 million IDIQ contract from the U.S. government. The award comes from the Air Force Research Laboratory and targets advanced optical payload and next generation space intelligence capabilities. The contract focuses on large aperture optical systems and AI enabled space data tools that differ from BlackSky's existing Gen 2 and Gen 3 offerings. For readers tracking NYSE:BKSY, this contract sits at the center of the...

Royalty Pharma (NasdaqGS:RPRX) has entered into a new R&D co-funding agreement with Johnson & Johnson to develop a novel autoimmune therapy. The company has also appointed a Head of Artificial Intelligence to expand the use of advanced analytics and data science across its operations. These announcements mark a shift toward greater involvement in drug development and data driven decision making. Royalty Pharma, known primarily for acquiring biopharma royalties, typically gives investors...

Regulators allowed the Hart Scott Rodino antitrust waiting period for Coterra Energy's merger with Devon Energy to expire, clearing a key hurdle. This approval means Coterra Energy (NYSE:CTRA) can move toward closing, with the company expected to become a wholly owned subsidiary of Devon. The companies currently anticipate closing the transaction in Q2 2026, subject to remaining customary conditions. Coterra Energy focuses on oil and gas exploration and production, an area where scale, cost...

Executive change triggers fresh look at Ardent Health stock Ardent Health (ARDT) shares are in focus after the company announced that Ethan Chernin, President of Hospital Services, departed on March 24, 2026, under its executive severance plan, prompting investors to reassess leadership stability and valuation. See our latest analysis for Ardent Health. With the latest close at $8.66, Ardent Health has seen a 1 month share price return of 8.26% decline and a 1 year total shareholder return of...

Insiders who purchased US$4.20m worth of Nomadar Corp. ( NASDAQ:NOMA ) shares over the past year recouped some of their...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

TOYO Co., Ltd. ( NASDAQ:TOYO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...

Why Phreesia’s latest guidance cut matters for investors Phreesia (PHR) has drawn fresh attention after issuing lower fiscal 2027 revenue guidance, tying the reset to weaker spending from pharmaceutical clients. The announcement triggered a sharp share price drop and several analyst downgrades. See our latest analysis for Phreesia. The lowered fiscal 2027 revenue outlook, combined with mixed fourth quarter results and analyst downgrades, has sharply shifted sentiment. A 7 day share price...

If you are wondering whether Penguin Solutions is priced attractively right now, the recent share moves give you plenty to think about. The stock last closed at US$20.69, with returns of 24.0% over 7 days, 9.0% over 30 days, 2.0% year to date and 36.2% over 1 year, while the 5 year return sits at a 26.0% decline and the 3 year return at 25.5%. These mixed time frame returns mean recent news flow is important context for understanding what the market is reacting to. Investors looking at...

EACO (EACO) has just posted its Q2 2026 numbers, with recent quarterly revenue running between about US$93.9 million and US$122.5 million and basic EPS ranging from US$1.33 to US$1.95 over the last six reported quarters. Trailing twelve month revenue sits at US$445.0 million and EPS at US$7.13. Over that same trailing period, earnings grew 73.4% year over year and net profit margin reached 7.8% compared with 5.4% a year earlier, setting the backdrop for investors to evaluate how sustainable...

For investors considering whether First Financial Bancorp at about US$28.08 is still good value or starting to look fully priced, this article walks through what the current market price might be implying about the stock. The share price sits around US$28.08, with returns of 3.0% over 7 days, 1.2% over 30 days, 11.9% year to date and 31.9% over the past year. This naturally raises questions about how much of the story is already priced in. Recent news flow around regional banks has kept...

If you are wondering whether F.N.B at US$16.86 is still offering value after its recent run, you are not alone. This article is intended to help you frame that question clearly. The stock has returned 4.2% over the last 7 days, is roughly flat over 30 days with a 0.2% decline, is down 1.9% year to date, and shows a 51.4% return over 1 year, 65.0% over 3 years and 56.4% over 5 years. Recent headlines around F.N.B have kept the stock on investors' radar, adding fresh context to these mixed...